Connect your AI

Zymeworks ZYME Lessee Operating Lease Liability Payments Due

Lessee Operating Lease Liability Payments Due at other companies

Nurix Therapeutics, Inc.NRIX

——

BioCryst PharmaceuticalsBCRX

——

iRhythm Holdings, Inc. IRTC

——

Other financials

Income statement

Revenue$2.4M-91.1%

Operating income-$47.1M-84.0%

Net income-$44.2M-95.1%

EPS (diluted)-$0.59-96.7%

Balance sheet

Cash & equivalents$244.3M+221%

Total debt$17.0M-7.7%

Total equity$163.6M-49.7%

Total assets$478.2M+12.4%

Cash flow

Operating cash flow-$45.7M-1,242%

CapEx$216.0K+1,250%

Free cash flow-$45.9M-1,242%

Valuation

Market cap$1.76B+125%

Enterprise value$1.53B+112%

P/S21.6×+13.2×

Profitability

Operating margin-140.4%+7.3pp

Net margin-126.3%+5.0pp

FCF margin-94.8%+15.5pp

Returns & leverage

Return on equity-42%+29.2pp

Debt / equity0.1×0.0×

Current ratio10.8×+6.1×

Where this comes from

Reported directly by Zymeworks in its filing.

Tagged under the XBRL concept us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue.

The official record: Zymeworks’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Zymeworks's lessee operating lease liability payments due.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Zymeworks's lessee operating lease liability payments due?: Zymeworks (ZYME) reported lessee operating lease liability payments due of $19.39M in Q1 2026.
How has Zymeworks's lessee operating lease liability payments due changed year-over-year?: Zymeworks's lessee operating lease liability payments due decreased by 8.4% year-over-year, from $21.18M to $19.39M.